Correction to: Nature https://doi.org/10.1038/s41586-023-06873-0 Published online 3 January 2024
In the version of the article initially published, three references were missing and have now been added as refs. 20–22: Schuster, M. et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Sci. Adv. 9, eadg3683 (2023); Martin-Loeches, I., Dale, G. E. & Torres, A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev. Anti-infect. Ther. 16, 259–268 (2018) and Li, D. & Schneider-Futschik, E. K. Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis. Antibiotics (Basel) 12, 484–505 (2023). These have been added to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zampaloni, C., Mattei, P., Bleicher, K. et al. Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 631, E17 (2024). https://doi.org/10.1038/s41586-024-07641-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-024-07641-4
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
